Linike Medical Group Ltd
Linike Medical Group Ltd Fundamental Analysis
Linike Medical Group Ltd (LNMG) shows moderate financial fundamentals with a PE ratio of 12.69, profit margin of 16.48%, and ROE of 1.66%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze LNMG's fundamental strength across five key dimensions:
Efficiency Score
WeakLNMG struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLNMG trades at attractive valuation levels.
Growth Score
ModerateLNMG shows steady but slowing expansion.
Financial Health Score
ExcellentLNMG maintains a strong and stable balance sheet.
Profitability Score
ModerateLNMG maintains healthy but balanced margins.
Key Financial Metrics
Is LNMG Expensive or Cheap?
P/E Ratio
LNMG trades at 12.69 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LNMG's PEG of 0.43 indicates potential undervaluation.
Price to Book
The market values Linike Medical Group Ltd at 0.21 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -12.93 times EBITDA. This is generally considered low.
How Well Does LNMG Make Money?
Net Profit Margin
For every $100 in sales, Linike Medical Group Ltd keeps $16.48 as profit after all expenses.
Operating Margin
Core operations generate 16.48 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.66 in profit for every $100 of shareholder equity.
ROA
Linike Medical Group Ltd generates $1.10 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Linike Medical Group Ltd generates limited operating cash flow of $-700.87K, signaling weaker underlying cash strength.
Free Cash Flow
Linike Medical Group Ltd generates weak or negative free cash flow of $-1.08M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
LNMG converts -23.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.69
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.21
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.59
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.45
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.01
vs 25 benchmark
How LNMG Stacks Against Its Sector Peers
| Metric | LNMG Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.69 | 19.11 | Better (Cheaper) |
| ROE | 1.66% | 821.00% | Weak |
| Net Margin | 16.48% | 1655.00% | Weak |
| Debt/Equity | 0.45 | 1.00 | Strong (Low Leverage) |
| Current Ratio | 4.30 | 659.22 | Strong Liquidity |
| ROA | 1.10% | 1976.00% | Weak |
LNMG outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Linike Medical Group Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical